1. home
  2. > लोकल ख़बरें
  3. > वेदांती बोले, नहीं आ सकता राम मंदिर पर अध्यादेश
replay trump newslist
up NEXT IN 5 SECONDS sports newslist
tap to unmute
00:00/00:00
NaN/0

Hetero, Cipla given go ahead to manufacture Remdesivir

Jun 21, 2020 12:26 IST

India's drug regulator on Saturday reportedly gave permission to pharma companies Hetero and Cipla to manufacture and market antiviral drug remdesivir for 'restricted emergency use' on hospitalised Covid-19 patients. Written informed consent of each patient is required before the use of remdesivir and results of additional clinical trials, active post-marketing surveillance data and reporting of serious adverse events have to be submitted. Cipla and Hetero Labs have entered into non-exclusive licensing agreements with US pharma giant Gilead Sciences, which is the patent holder of the drug.

लोकल ख़बरें